Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...

The vaccine, manufactured by US pharmaceutical giant Moderna, was found to slash the risk of severe illness from respiratory ...

The stocks in the Hong Kong pharmaceutical sector have recently shown an upward trend. As global capital flows positively ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

Emily and Joey Spadafore watched helplessly as their 3-month-old son, Benjamin, battled RSV for a week in the hospital.

Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for ...

Spring is just around the corner, but this year's flu season is still clinging on and causing misery for millions of people ...

Expectant mums and elderly people who haven’t yet had their vaccination against the life-threatening RSV virus that is spreading in London ...

In this piece, we include reporting tips, how vaccine side effects are tracked in the U.S., and what research shows about the ...

A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.